1.
Loffroy R,
Favelier S,
Cherblanc V,
Estivalet L.
C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients.
Quant Imaging Med Surg.
2013;3(4):196.
2.
Romaric Loffroy,
MD,
PhD,
MingDe Lin,
PhD,
Gayane Yenokyan,
PhD,
Pramod P.
Rao,
MD,
Nikhil Bhagat,
MD,
Niels Noordhoek,
PhD.
intraprocedural c-arm Dual-Phase c one-Beam c T: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma?rocedural C-Arm.pdf.
Radiology.
2013;266(2):636-48.
3.
Lencioni R,
Llovet J.
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma.
Semin Liver Dis.
febrero de 2010;30(01):052-60.
4.
Ferrer Puchol MD,
la Parra C,
Esteban E,
Vaño M,
Forment M,
Vera A,
et al.
Quimioembolización del hepatocarcinoma: partículas cargadas frente a quimioembolización convencional.
Radiología.
mayo de 2011;53(3):246-53.
5.
Riaz A,
Memon K,
Miller FH,
Nikolaidis P,
Kulik LM,
Lewandowski RJ,
et al.
Role of the EASL,
RECIST,
and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation.
J Hepatol.
2011;54(4):695-704.
6.
Llovet JM,
Fuster J,
Bruix J,
of the Barcelona-Clinic Liver Cancer Group.
The Barcelona approach: Diagnosis,
staging,
and treatment of hepatocellular carcinoma.
Liver Transpl.
febrero de 2004;10(S2):S115-S120.
7.
Lencioni R,
Baere T,
Burrel M,
Caridi JG,
Lammer J,
Malagari K,
et al.
Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations.
Cardiovasc Intervent Radiol.
octubre de 2012;35(5):980-5.
8.
Madoff DC,
Hicks ME,
Vauthey J-N,
Charnsangavej C,
Morello FA,
Ahrar K,
et al.
Transhepatic Portal Vein Embolization: Anatomy,
Indications,
and Technical Considerations1.
Radiographics.
2002;22(5):1063-76.